Brand Intelligence Graph
Company Overview
About Alveus Therapeutics
Alveus Therapeutics is applying mRNA medicine to pulmonary diseases by developing inhaled mRNA formulations that deliver protein replacement or gene editing instructions directly to lung cells. Unlike systemic mRNA therapeutics that require IV infusion and liver targeting, Alveus's inhaled approach delivers mRNA locally to lung epithelial cells, enabling treatment of diseases like idiopathic pulmonary fibrosis (IPF), COPD, and cystic fibrosis with potentially lower doses and fewer systemic side effects.
Business Model & Competitive Advantage
The company's lipid nanoparticle formulations for pulmonary delivery draw on lessons from COVID-19 mRNA vaccine manufacturing and Moderna's pulmonary delivery research. Alveus was founded in 2023 by pulmonology and mRNA delivery experts and raised $150M in a 2025 Series A, reflecting investor enthusiasm for respiratory applications of mRNA technology following vaccine success.
Competitive Landscape 2025–2026
IPF affects 100,000+ patients annually in the U.S. with no curative options — current approved therapies only slow progression. Alveus's IND-enabling studies target a 2026 first-in-human milestone for its lead IPF program, with pipeline expansion into RSV and influenza mRNA vaccines that leverage the inhaled delivery platform.
Key Differentiators
Emerging Innovator
Alveus Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Compare Alveus Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Alveus Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Alveus Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Alveus Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →